29 results on '"Javierre G"'
Search Results
2. 272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
3. 165P EPclin, OncotypeDx and Prosigna in lobular breast cancer (ILC): Is there an association with Ki67?
4. 202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
5. 143P Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2+ breast cancer. A systematic review and network meta-analysis (NMA)
6. 294P Adult population with BRAF-mutated (BRAFmut) and NF1-mutated (NF1mut) gliomas. Analysis of the potential role of targeted therapy (TT) in these patients (pts)
7. 445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor
8. 1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital
9. 1724P Prognostic parameters at admission as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts) of a tertiary hospital
10. 152P Meta-analysis of the prognostic value of circulating tumor DNA (ctDNA) in patients (pts) with early breast cancer (EBC)
11. 426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
12. 145P High-risk breast cancer patients with RAD51-low tumors are characterized by good prognosis
13. 438P Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
14. 880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
15. 1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
16. 1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis
17. 1068P Rescue chemotherapy (CT) after immune-oncology (IO) drugs in patients (pts) with refractory solid tumours: A propensity score (PS) matched cohort study
18. 1154TiP A randomized, prospective, multicenter study to assess the impact of early detection of asymptomatic brain metastases (mets) vs standard follow-up on symptomatic brain mets free survival (SBMFS) in pts with previously untreated, unresectable or metastatic melanoma (MM)
19. 1858P Role of depression and quality of life (QOL) status as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts)
20. 1807P Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital
21. 938P Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
22. 1072P Beyond classical surrogate endpoints in trials of PD1/PD-L1 immune checkpoint inhibitors (ICI) plus chemotherapy (CT)
23. Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
24. Efficacy of Cetuximab Based Chemotherapy after Immunotherapy Treatments (IT) in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Patients (pts)
25. Outcomes of vulvar cancer (VC) patients (pts): Impact of clinicopathological factors and HPV status
26. Impact of chemotherapy (CT) in heavily pretreated BRCA1/2 mutation carrier ovarian cancer (BMCOC) patients (pts)
27. Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials
28. Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)
29. Achievement of complete response (CR) in metastatic or recurrent cervical cancer (MRCC): Does it matter?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.